Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc. scores highest on Price (40) and lowest on Earnings (27). Its PosiPenta is 34.56 out of 100, weaker than most similar companies.
On the Penta Grid this week, Aligos Therapeutics, Inc. is Grid #681 of 837 in the Healthcare sector in United States, and Grid #3,330 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Aligos Therapeutics, Inc. | 34.56 | 40 | 27 | 34 | 37 | 35 |
| Metagenomi Therapeutics, Inc. | 38.59 | 49 | 34 | 17 | 39 | 55 |
| BioStem Technologies, Inc. | 51.71 | 79 | 46 | 25 | 49 | 60 |
| Nortech Systems Incorporated | 59.19 | 63 | 79 | 59 | 54 | 41 |
| TransCode Therapeutics, Inc. | 39.82 | 49 | 40 | 15 | 61 | 34 |
| Filana Therapeutics, Inc. | 40.75 | 45 | 53 | 15 | 67 | 25 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -0.66 |
| P/B ratio | 0.95 |
EEarnings
| Trailing EPS | ₹-701.84 |
| Forward EPS | ₹-496.90 |
NNitro
| Price | 460.31 |
| 52-week high | 1296.55 |
| 52-week low | 376.97 |
| Fall from 52-week high | 64.5% |
TTorque
| Return on equity (ROE) | -113.59% |
| Debt-to-equity | 0.11 |
AAnchor
| Beta (price swings) | 2.36 |
| Market cap | ₹287 Cr |
| Insider holding | 10.64% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Aligos Therapeutics, Inc.'s PosiPenta score?
Aligos Therapeutics, Inc.'s PosiPenta is 34.56 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does Aligos Therapeutics, Inc. stand on the Penta Grid?
On the Penta Grid this week, Aligos Therapeutics, Inc. is Grid #681 of 837 in the Healthcare sector in United States, and Grid #3,330 of 4,000 in United States.
Which PosiPenta pillar is strongest for Aligos Therapeutics, Inc.?
Price (valuation), with a score of 40 out of 100: weaker than most similar companies.
Which PosiPenta pillar is weakest for Aligos Therapeutics, Inc.?
Earnings (growth), with a score of 27 out of 100: weaker than most similar companies.
Has Aligos Therapeutics, Inc.'s PosiPenta changed since last week?
Yes, it rose 3.02 points, from 31.54 to 34.56.
PositoAI is for research and education only and is not investment advice.